Related Experiment Video
Updated: Oct 23, 2025
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Should timing be considered before abandoning convalescent plasma in covid-19? Results from the Turkish experience
İhsan Ateş1, Abdulsamet Erden2, Serdar Can Güven2
1Ministry of Health Ankara City Hospital, Department of Internal Medicine, Ankara, Turkey.
Insights
COVID-19 convalescent plasma (CCP) therapy shows improved outcomes when administered within seven days of symptom onset. Early CCP treatment reduced anti-inflammatory drug use and hospital stays in hospitalized patients.
Area of Science:
- Infectious Diseases
- Immunology
- Critical Care Medicine
Background:
- Contradictory results exist regarding the efficacy of convalescent plasma therapy for COVID-19.
- The timing of COVID-19 convalescent plasma (CCP) administration appears critical for therapeutic success.
Purpose of the Study:
- To compare disease outcomes in hospitalized COVID-19 patients receiving CCP within three or seven days of symptom onset versus those treated later.
- Evaluate the impact of early versus delayed CCP administration on clinical outcomes.
Main Methods:
- A multicenter retrospective study involving 223 hospitalized COVID-19 patients.
- Patients receiving CCP were compared to a control group receiving standard of care (SOC).
- Subgroup analysis based on CCP administration within 3, 7, or after 7 days of symptom onset.
Main Results:
- Patients receiving CCP within seven days of symptom onset showed significantly lower rates of anti-inflammatory treatment initiation (38.1% vs. 62.7%).
- Hospitalized patients treated with CCP within seven days experienced a significantly shorter length of hospital stay (median 8 days vs. 9.5 days).
Conclusions:
- COVID-19 convalescent plasma therapy demonstrates potential benefits when administered within seven days of symptom onset.
- Early intervention with CCP may lead to improved clinical outcomes in hospitalized COVID-19 patients.
Introductions:
Results with convalescent plasma therapy in coronavirus disease 2019 (COVID-19) have been contradictory. Timing seems to be an important factor for COVID-19 convalescent plasma(CCP) to be effective. Aim of this study is to compare disease outcomes in hospitalized COVID-19 patients who were treated with CCP within first three or seven days of symptoms to patients with symptoms longer than seven days.
Material And Methods:
A multicenter retrospective study was conducted to evaluate disease outcomes in hospitalized COVID-19 patients who received CCP in addition to standard of care (SOC) approach. Patients were subgrouped according to time of CCP administration; within three days of symptoms, seven days of symptoms and after seven days of symptoms. A control group was formed from age, gender and comorbidity matched hospitalized patients who received SOC treatments without CCP. Length of hospital stay, rates of anti-inflammatory treatment initiation, intensive care unit (ICU) admission and mortality was set as outcome measures.
Results:
A total of 223 patients were enrolled in this study, 113 patients received CCP (38 within three days, 63 within seven days, 50 after seven days of symptom onset). Rate of anti-inflammatory treatment initiation was significantly lower (38.1 % vs 62.7 %, p = 0.002, relative risk, 0.60,73; 95 % confidence interval [CI], 0.42 to 0.85) and length of hospital stay was significantly shorter (median(IQR) 8(4) days vs 9.5(5.25) days, p = 0.0025) in patients who received CCP within seven days of symptom onset when compared to SOC group.
Conclusion:
CCP therapy may provide better outcomes when applied within seven days of symptoms.
More Related Videos
10:48Isolation and Cryopreservation of Highly Viable Human Peripheral Blood Mononuclear Cells From Whole Blood: A Guide for Beginners
Published on: October 25, 2024
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Related Concept Videos
02:45Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:14Myocarditis III: Medical Management